The absolute risk reduction in fatal and nonfatal CHD with pravastatin treatment was @ % ( @ % CI = -@ to @ % ) in the low homocysteine group and @ % ( @ % CI = @-@ @ % ) in the high homocysteine group ( difference @ % , @ % CI = @-@ @ , P = @ ) .